nach oben

Erschienen in:

21.07.2021 | Research Article

Postoperative radiotherapy after upfront radical prostatectomy: debated issues at a turning point—a survey exploring management trends on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology)

verfasst von: G. Francolini, G. Timon, F. Matrone, G. Marvaso, L. Nicosia, L. Ognibene, A. Vinciguerra, L. E. Trodella, C. Franzese, P. Borghetti, B. A. Jereczek-Fossa, S. Arcangeli

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Postoperative prostate cancer patients are a heterogeneous population, and many prognostic factors (e.g., local staging, PSA kinetics, margin status, histopathological features) may influence their clinical management. In this complex scenario, univocal recommendations are often lacking. For these reasons, the present survey was developed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) to collect the opinion of Italian radiation oncologists and delineate a representation of current clinical practice in our country.

Methods

A questionnaire was administered online to AIRO (Italian Association of Radiotherapy and Clinical Oncology) members registered in 2020 with a clinical interest in uro-oncological disease.

Results

Sixty-one per cent of AIRO members answered the proposed survey. Explored topics included career and expertise, indications to adjuvant RT, additional imaging in biochemical recurrence setting, use of salvage radiotherapy (SRT), management of clinically evident locoregional recurrence and future considerations.

Conclusions

Overall, good level of agreement was found between participants for most of the topics. Most debated issues regarded, as expected, implementation of new imaging methods in this setting. Notably, trend in favour of early SRT vs. immediate adjuvant RT was underlined, and preference for global evaluation rather than isolated risk factors for RT indications was noticed.

Buglione M, Noale M, Bruni A, Antonelli A, Bertoni F, Corvo’; R, Ricardi U, Borghetti P, Maddalo M, Simeone C, Mazzeo E, Porreca A, Serni S, Bassi P, Gacci M, Mirone V, Montironi R, Tubaro A, Berruti A, Conti GN, Maggi S, Magrini SM, Triggiani L; Pros-IT CNR study group. Treatment paths for localised prostate cancer in Italy: the results of a multidisciplinary, observational, prospective study (Pros-IT CNR). PLoS ONE. 2019;14(11):e0224151.CrossRef

Tyson MD 2nd, Andrews PE, Ferrigni RF, et al. Radical prostatectomy trends in the United States: 1998 to 2011. Mayo Clin Proc. 2016;91(1):10–62.CrossRef

https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 4 Sep 2020

Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–62.CrossRef

Karakiewicz PI, Eastham JA, Graefen M, et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology. 2005;66:1245–50.CrossRef

Thompson IM, Valicenti RK, Albertsen P, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013;190:441–9.CrossRef

Arcangeli S, Ramella S, De Bari B, Franco P, Alongi F, D’Angelillo RM. A cast of shadow on adjuvant radiotherapy for prostate cancer: a critical review based on a methodological perspective. Crit Rev Oncol Hematol. 2016;97:322–7.CrossRef

Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956–62.CrossRef

Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380(9858):2018–27.CrossRef

10.

Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96–02/AUO AP 09/95 trial. Eur Urol. 2014;66(2):243–50.CrossRef

11.

Hackman G, Taari K, Tammela TL, et al. Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension. Eur Urol. 2019;76(5):586–95.CrossRef

12.

Parker C, Clarke NW, Cook A, Kynaston HG, Meidahl Petersen P, Cross W, Persad R, Catton C, Logue J, Payne H, Saad F, Brasso K, Lindberg H, Zarkar A, Raman R, Roder MA, Heath C, Parulekar WR, Parmar MKB, Sydes MR. Timing of radiotherapy (RT) after radical prostatectomy (RP): first results from the RADICALS RT randomised controlled trial (RCT). Ann Oncol. 2019;30(suppl_5):851–934. https://doi.org/10.1093/annonc/mdz394.CrossRef

13.

Kneebone A, Fraser-Browne C, Delprado W, Duchesne G, Fisher R, Frydenberg M, Haworth A, Herschtal A, Joseph DJ, Lim TS, Martin JM, Millar JL, Sidhom M, Spry N, Tang CI, Turner S, Williams SG, Wiltshire KL, Woo H, Pearse M. A Phase III multi-centre randomised trial comparing adjuvant versus early salvage radiotherapy following a radical prostatectomy: results of the TROG 0803 and ANZUP “RAVES” Trial. Internat J Radiat Oncol Biol Physics. 2019;105(suppl_37):S37–8.CrossRef

14.

Vale CL, Brihoum M, Chabaud S, Cook A, Fisher D, Forcat S, Fraser-Browne C, Herschtal A, Kneebone A, Nénan S, Parker C, Parmar MKB, Pearse M, Richaud P, Rogozińska E, Sargos P, Sydes MR, Tierney JF. Adjuvant or salvage radiotherapy for treatment of localised prostate cancer? A prospectively planned aggregate. Ann Oncol. 2019;30(suppl_5):851–934. https://doi.org/10.1093/annonc/mdz394.CrossRef

15.

Morris MJ, Pouliot F, Saperstein L, Rowe SP, Gorin MA, Josephson DY, Wong JYC, Carroll P, Lin T, Stambler N, Wong V, Jensen JD, Siegel BA. A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR). J Clin Oncol. 2019;37(suppl15):157–60.

16.

Francolini G, Detti B, Bottero M, et al. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series [published online ahead of print, 2020 Jun 29]. Clin Transl Oncol. 2020. https://doi.org/10.1007/s12094-020-02427-2.CrossRefPubMed

17.

Spratt DE, Dess RT, Zumsteg ZS, et al. A systematic review and framework for the use of hormone therapy with salvage radiation therapy for recurrent prostate cancer. Eur Urol. 2018;73(2):156–65.CrossRef

18.

Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, Tombal B, Gillessen S. On behalf of the ESMO guidelines commitee, prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020. https://doi.org/10.1016/j.annonc.2020.06.011.CrossRefPubMed

19.

Ploussard G, Drouin SJ, Rode J, Allory Y, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L. Location, extent, and multifocality of positive surgical margins for biochemical recurrence prediction after radical prostatectomy. World J Urol. 2014;32(6):1393–400.CrossRef

20.

Abdollah F, Boorjian S, Cozzarini C, et al. Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification. Eur Urol. 2013;64(4):557–64.CrossRef

21.

Hoffman KE, Nguyen PL, Chen MH, et al. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trial. J Urol. 2011;185(1):116–20.CrossRef

22.

Cozzarini C, Fiorino C, Di Muzio N, Valdagni R, Salonia A, Alongi F, Broggi S, Guazzoni G, Montorsi F, Rigatti P, Calandrino R, Fazio F. Hypofractionated adjuvant radiotherapy with helical tomotherapy after radical prostatectomy: planning data and toxicity results of a Phase I-II study. Radiother Oncol. 2008;88(1):26–33.CrossRef

23.

Fersino S, Tebano U, Mazzola R, Giaj-Levra N, Ricchetti F, Di Paola G, Fiorentino A, Sicignano G, Naccarato S, Ruggieri R, Cavalleri S, Alongi F. Moderate hypofractionated postprostatectomy volumetric modulated arc therapy with daily image guidance (VMAT-IGRT): a mono-institutional report on feasibility and acute toxicity. Clin Genitourin Cancer. 2017;15(4):e667–73.CrossRef

24.

Barra S, Belgioia L, Marcenaro M, Callegari S, Pastorino A, Trapani L, Cavagnetto F, Garelli S, Corvò R. Moderate hypofractionated radiotherapy after prostatectomy for cancer patients: toxicity and clinical outcome. Cancer Manag Res. 2018;12(10):473–80.CrossRef

25.

Chin S, Fatimilehin A, Walshaw R, Argarwal A, Mistry H, Elliott T, Logue J, Wylie J, Choudhury A. Ten-year outcomes of moderately hypofractionated salvage postprostatectomy radiation therapy and external validation of a contemporary multivariable nomogram for biochemical failure. Int J Radiat Oncol Biol Phys. 2020;107(2):288–96.CrossRef

26.

Tandberg DJ, Oyekunle T, Lee WR, Wu Y, Salama JK, Koontz BF. Postoperative radiation therapy for prostate cancer: comparison of conventional versus hypofractionated radiation regimens. Int J Radiat Oncol Biol Phys. 2018;101:396–405.CrossRef

27.

Macchia G, Siepe G, Capocaccia I, et al. Hypofractionated postoperative IMRT in prostate carcinoma: a phase I/II study. Anticancer Res. 2017;37(10):5821–8.PubMed

28.

https://clinicaltrials.gov/ct2/show/NCT03274687

29.

Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the Long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys. 2016;96(4):759–69.CrossRef

30.

Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR Jr, Shipley WU, Sandler HM. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1504–15.CrossRef

31.

Sargos P, Chabaud S, Latorzeff I, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1341–52.CrossRef

32.

Parker CC, Clarke NW, Cook AD, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396(10260):1413–21.CrossRef

33.

Mena E, Lindenberg ML, Shih JH, et al. Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. Eur J Nucl Med Mol Imaging. 2018;45(1):4–11. https://doi.org/10.1007/s00259-017-3818-x.CrossRefPubMed

34.

Morris M, Carroll P, Saperstein L, Pouliot F, Josephson D, Wong J, Pantel A, Cho S, Gage K, Piert M, Iagaru A, Pollard J, Wong V, Jensen J, Stambler N, Gorin M, Siegel B. Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): results from a phase III, prospective, multicenter study (CONDOR). J Clin Oncol. 2020;38:5501. https://doi.org/10.1200/JCO.2020.38.15_suppl.5501.CrossRef

35.

Koschel S, Sutherland T, Wong L, et al. Impact of 18F-DCFPyL PET scanning in patients undergoing post prostatectomy radiotherapy (IMPPORT)—preliminary results of a prospective multi-site trial. Eur Urol Suppl. 2019;18(1):e1947–8.CrossRef

36.

Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT] [PSMA-SRT] [published correction appears in BMC Cancer. 2019;21;19(1):97]. BMC Cancer. 2019;19(1):18.CrossRef

37.

Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, Supiot S, Belkacemi Y, Peiffert D, Allouache N, Dubray BM, Servagi-Vernat S, Suchaud JP, Crehange G, Guerif S, Brihoum M, Barbier N, Graff-Cailleaud P, Ruffion A, Dussart S, Ferlay C, Chabaud S. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20(12):1740–9.CrossRef

38.

Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM; NRG Oncology RTOG. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417–28.CrossRef

39.

Pollack A, Karrison TG, Balogh AG Jr, et al. Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG oncology/RTOG 0534 SPPORT Trial. Int J Radiat Oncol Biol Phys. 2018;102(5):1605.CrossRef

40.

Parker C, Sydes MR, Catton C, et al; (RADICALS Trial Management Group). Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int. 2007;99(6):1376–9.CrossRef

41.

Bruni A, Ingrosso G, Trippa F, et al. Macroscopic locoregional relapse from prostate cancer: which role for salvage radiotherapy? Clin Transl Oncol. 2019;21(11):1532–7.CrossRef

42.

Francolini G, Jereczek-Fossa BA, Di Cataldo V, Simontacchi G, Marvaso G, Zerella MA, Gentile P, Bianciardi F, Allegretta S, Detti B, Masi L, Lo Russo M, Livi L. Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series. BJU Int. 2020;125(3):417–25.CrossRef

43.

De Bleser E, Jereczek-Fossa BA, Pasquier D, et al. Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy. Eur Urol. 2019;76(6):732–9.CrossRef

44.

De Bruycker A, Spiessens A, Dirix P, et al. PEACE V - salvage treatment of oligorecurrent nodal prostate cancer metastases (STORM): a study protocol for a randomized controlled phase II trial. BMC Cancer. 2020;20(1):406 (Published 2020 May 12).CrossRef

45.

Swanson GP, Riggs M, Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol. 2007;25:110–4.CrossRef

Titel: Postoperative radiotherapy after upfront radical prostatectomy: debated issues at a turning point—a survey exploring management trends on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology)
verfasst von: G. Francolini
G. Timon
F. Matrone
G. Marvaso
L. Nicosia
L. Ognibene
A. Vinciguerra
L. E. Trodella
C. Franzese
P. Borghetti
B. A. Jereczek-Fossa
S. Arcangeli
Publikationsdatum: 21.07.2021
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 12/2021
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-021-02665-y

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Postoperative radiotherapy after upfront radical prostatectomy: debated issues at a turning point—a survey exploring management trends on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology)